-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA extends review of Belite Bio's tinlarebant by three months to May 12, 2027

PUBT·11/20/2026 13:00:30
Listen to the news
FDA extends review of Belite Bio's tinlarebant by three months to May 12, 2027
  • FDA extended review of Belite Bio's tinlarebant application for Stargardt disease type 1 by three months to May 12, 2027.
  • The extension gives the agency additional time to review information supporting the new drug application.
  • If no major deficiencies emerge, FDA plans to communicate proposed labeling requests and anticipated postmarketing requirements by April 12, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200800PRIMZONEFULLFEED9881989) on November 20, 2026, and is solely responsible for the information contained therein.